A new survey by the American College of Emergency Physicians, conducted in October, revealed that 87% of emergency physicians say they are more stressed since the start of the COVID-19 pandemic. In addition, 72% report experiencing more professional burnout.
Recurrent bacterial vaginosis is a problem that affects many women, with an estimated 50% of women developing a recurrence within 12 months of treatment. The authors of this study tested the efficacy of a novel product, Lactobacillus crispatus CTV-05 (Lactin-V), in reducing bacterial vaginosis recurrence in this phase 2b clinical trial.
IqYmune is a highly purified 10% concentration of human immunoglobulin obtained from healthy volunteers. It appears to have similar efficacy in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as conventional intravenous immunoglobulin, with 76% of the study patients showing a significant improvement in a standardized disability score.
In a multicenter, retrospective analysis of patients in a multiple sclerosis (MS) registry, the authors described the clinical characteristics and risks associated with severity of complications from COVID-19 infection in patients with MS.
Scrambler therapy appears to significantly reduce central neuropathic pain for patients with neuromyelitis optica spectrum disorder, although pain reduction is not shown to be sustained for more than 30 days after treatment.
The research community’s decades of work to build public trust in IRB oversight and the clinical trial process has reached one of its greatest challenges during the COVID-19 pandemic. Misinformation spread through social media and some media outlets, as well as contradictory instructions and information from political and public health officials, have helped create distrust. Through the spring of 2020, misinformation about hydroxychloroquine as a COVID-19 therapeutic proliferated after President Trump spoke about it as a cure.